Galinpepimut-S Versus Investigator's Choice of Best Available Therapy for Maintenance in AML CR2/CRp2
Study sponsor: Sellas Life Sciences Group
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2025-12Estimated
Enrollment · participants127Actual
Source updated2025-10-01Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.